Antibe Therapeutics Inc (ATBPF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
(Values in U.S. thousands)
| 12-2023 | 09-2023 | 06-2023 | 03-2023 | 12-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 8,327 | 3,088 | 6,540 | 5,110 | 7,763 |
| Marketable Securities | 9,964 | 17,688 | 18,977 | 24,312 | 23,465 |
| Receivables | 1,135 | 1,222 | 1,148 | 1,252 | 1,173 |
| TOTAL | $20,633 | $23,178 | $28,099 | $31,430 | $32,829 |
| Non-Current Assets | |||||
| Intangibles | 19,353 | 19,640 | 19,601 | 19,935 | 19,429 |
| Other Non-Current Assets | 1,406 | 2,053 | 2,014 | 2,015 | 2,102 |
| TOTAL | $20,759 | $21,693 | $21,615 | $21,950 | $21,531 |
| Total Assets | $41,392 | $44,871 | $49,713 | $53,379 | $54,360 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 2,052 | 2,135 | 3,280 | 2,091 | 2,090 |
| TOTAL | $2,052 | $2,135 | $3,280 | $2,091 | $2,090 |
| Non-Current Liabilities | |||||
| TOTAL | $20,292 | $20,593 | $20,552 | $20,903 | $20,372 |
| Total Liabilities | $22,344 | $22,729 | $23,832 | $22,994 | $22,463 |
| Shareholders' Equity | |||||
| Common Shares | 103,996 | 105,521 | 105,308 | 107,036 | 103,860 |
| Retained earnings | -106,854 | -105,300 | -101,363 | -98,716 | -93,595 |
| Other shareholders' equity | 7,538 | 7,650 | 7,634 | 7,765 | 7,568 |
| TOTAL | $19,048 | $22,142 | $25,881 | $30,386 | $31,898 |
| Total Liabilities And Equity | $41,392 | $44,871 | $49,713 | $53,379 | $54,360 |